FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

                                   (Mark One)
               X Quarterly Report Pursuant to Section 13 or 15(d)
                                        -
                     of the Securities Exchange Act of 1934

                      For Quarter Ended: February 29, 2000
                                         -----------------
                                       OR
               _ Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                         Georgia                       22-2408354
             (State or other jurisdiction of        (I.R.S. Employer
               incorporation or organization)      Identification No.)

     3130 Gateway Drive P.O. Box 5625 Norcross, Georgia      30091-5625
           (Address of principal executive offices)          (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X      No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

         As of April 3, 2000: Common Stock, $. 10 Par Value - 7,867,617
<PAGE>

                                  IMMUCOR, INC.
                      Condensed Consolidated Balance Sheets
<TABLE>
<CAPTION>

                                                                       February 29, 2000    May 31, 1999
ASSETS                                                                 (Unaudited)            (Audited)
                                                                     -----------------      --------------
<S>                                                                        <C>                     <C>

Current assets:
    Cash and cash equivalents                                             $ 2,975,690         $ 2,793,592
    Accounts receivable, net                                               24,571,119          21,573,846
    Accounts receivable from former officer and director                            -             140,946
    Inventories                                                            16,976,203          16,065,190
    Income taxes receivable                                                   413,815             553,451
    Deferred income taxes                                                     915,234             907,530
    Prepaid expenses and other                                              1,485,625           1,587,817
                                                                     -----------------      --------------
        Total current assets                                               47,337,686          43,622,372

Long-term investment, at cost                                               1,000,000           1,000,000

Property and equipment, at cost                                            22,607,212          20,195,158
    less accumulated depreciation                                          (6,985,311)         (5,068,996)
                                                                     -----------------      --------------
                                                                           15,621,901          15,126,162

Deferred income taxes                                                       1,257,192           1,108,279

Other assets, net                                                           3,095,760           2,934,409

Deferred licensing costs, net                                               2,347,158           2,307,837

Excess of cost over net tangible assets acquired, net                      32,781,936          33,634,458
                                                                     -----------------      --------------

Total Assets                                                            $ 103,441,633        $ 99,733,517
                                                                     =================      ==============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
    Current portion of borrowings under bank line of credit agreements    $ 1,786,109         $ 1,619,312
    Current portion of long-term debt                                       3,157,868           5,000,062
    Note payable to related party                                                   -           1,637,495
    Current portion of capital lease obligations                              479,936             194,476
    Accounts payable                                                        7,607,997          10,039,489
    Income taxes payable                                                    1,105,826              27,739
    Accrued salaries and wages                                                974,425           1,125,216
    Deferred income taxes                                                     118,280             118,280
    Other accrued liabilities                                               2,438,267           2,719,496
                                                                     -----------------      --------------
        Total current liabilities                                          17,668,708          22,481,565


Long-term debt, including borrowings under bank line of credit agreements  33,031,079          30,747,855
Capital lease obligations                                                   1,323,362             800,117

Deferred income taxes                                                       3,044,606           3,024,550

Other liabilities                                                           2,585,062           2,626,763

Shareholders' equity:
    Common stock, $.10 par value                                              786,199             748,841
    Additional paid-in capital                                             19,801,460          16,945,885
    Retained earnings                                                      28,995,808          25,498,721
    Accumulated other comprehensive loss                                   (3,794,651)         (3,140,780)
                                                                     -----------------      --------------

        Total shareholders' equity                                         45,788,816          40,052,667
                                                                     -----------------      --------------

Total Liabilities and Shareholders' equity                              $ 103,441,633        $ 99,733,517
                                                                     =================      ==============
</TABLE>

See accompanying notes.
<PAGE>


                                                   IMMUCOR, INC.
                                    Condensed Consolidated Statements of Income
                                                    (Unaudited)
<TABLE>
<CAPTION>


                                                    Three Months Ended                      Nine Months Ended
                                           February 29,       February 28,         February 29,       February 28,
                                               2000               1999                 2000               1999
                                          ----------------   ----------------     ----------------   ---------------
<S>                                             <C>                 <C>                   <C>               <C>

Net sales                                     $19,201,121        $16,758,106          $58,380,907       $40,782,061
Cost of sales                                   9,025,124          7,589,998           27,248,423        18,558,724
                                           ----------------   ----------------     ----------------   ---------------

Gross profit                                   10,175,997          9,168,108           31,132,484        22,223,337

Research and development                          553,079            413,335            1,283,336         1,000,707
Selling and marketing                           2,999,163          3,045,981            8,919,250         7,337,310
Distribution                                    1,422,632            964,498            4,421,592         2,262,647
General and administrative                      2,732,826          2,348,759            7,972,114         6,118,292
Merger-related expenses                                 0            120,331                    0           432,692
Amortization expense                              453,352            329,543            1,353,600           710,777
                                          ----------------   ----------------     ----------------   ---------------
Total operating expenses                        8,161,052          7,222,447           23,949,892        17,862,425
                                          ----------------   ----------------     ----------------   ---------------

Income from operations                          2,014,945          1,945,661            7,182,592         4,360,912

Interest income                                     3,967             19,697               14,582           305,630
Interest expense                                 (707,131)          (516,843)          (2,146,657)         (903,322)
Other income                                       30,760             27,892              180,847            79,344

                                          ----------------   ----------------     ----------------   ---------------
Total other                                      (672,404)          (469,254)          (1,951,228)         (518,348)
                                          ----------------   ----------------     ----------------   ---------------

Income before income taxes                      1,342,541          1,476,407            5,231,364         3,842,564

Income taxes                                      504,645            500,310            1,734,277         1,522,388
                                          ----------------   ----------------     ----------------   ---------------

Net income                                       $837,896           $976,097           $3,497,087        $2,320,176
                                          ================   ================     ================   ===============

Earnings per share:
   Basic                                            $0.11              $0.13                $0.45             $0.30
                                          ================   ================     ================   ===============

   Diluted                                          $0.10              $0.13                $0.40             $0.29
                                          ================   ================     ================   ===============

Weighted average shares outstanding:
   Basic                                        7,816,012          7,459,589            7,715,560         7,711,459
                                          ================   ================     ================   ===============

   Diluted                                      8,671,191          7,720,680            8,685,157         7,981,352
                                          ================   ================     ================   ===============

</TABLE>

See accompanying notes.

<PAGE>

                                  IMMUCOR, INC.
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                                           Nine Months Ended
                                                                                  February 29,          February 28,
                                                                                      2000                  1999
                                                                                 ----------------      ----------------
<S>                                                                                     <C>                   <C>

OPERATING ACTIVITIES:
  Net income                                                                          $3,497,087            $2,320,176
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                                                                     2,067,921             1,219,311
      Amortization                                                                     1,353,600               710,777
      Changes in assets and liabilities:
         Accounts receivable                                                          (2,951,808)           (3,755,190)
         Accounts receivable from former officer and director                            140,946               526,467
         Income tax receivable                                                           139,636               233,246
         Inventories                                                                    (911,013)           (1,955,139)
         Other current assets                                                           (198,781)              245,457
         Accounts payable                                                             (2,476,959)            1,294,808
         Income taxes payable                                                          1,078,087               (89,989)
         Other current liabilities                                                      (501,151)              385,006
                                                                                 ----------------      ----------------

Cash provided by operating activities                                                  1,237,565             1,134,930

INVESTING ACTIVITIES:
  Purchase of / deposits on property and equipment                                    (2,797,064)           (2,344,313)
  Cash paid for acquisitions                                                            (673,225)          (25,658,125)
  Acquisition-related severance                                                          (82,756)           (1,957,640)
  Decrease in other assets                                                               (15,028)           (3,222,946)
                                                                                 ----------------      ----------------

Cash used in investing activities                                                     (3,568,073)          (33,183,024)

FINANCING ACTIVITIES:
  Borrowings under line of credit agreements                                           5,642,883            25,200,000
  Repayment of notes payable                                                          (5,853,757)           (1,299,200)
  Exercise of stock options and warrants  (373,582 and 180,899 shares, respectively)   2,892,933             1,330,996
  Purchase and retirement of stock  (822,800 shares)                                           -            (7,354,007)
                                                                                 ----------------      ----------------

Cash provided by (used in) financing activities                                        2,682,059            17,877,789

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                                 (169,453)               75,162
                                                                                 ----------------      ----------------

INCREASE IN CASH AND CASH EQUIVALENTS                                                    182,098           (14,095,143)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                       2,793,592            15,816,217
                                                                                 ----------------      ----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                            $2,975,690            $1,721,074
                                                                                 ================      ================


Noncash investing and financing activities:
  Fair value of assets acquired, net of cash                                                               $17,757,750
  Cost in excess of assets acquired                                                                         17,078,722
  Liabilities assumed                                                                                       (9,178,347)
                                                                                                       ----------------
  Net cash paid for acquisition                                                                            $25,658,125



</TABLE>

<PAGE>


                                 IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
1999, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation  have been  included.  Operating  results for the nine month period
ended February 29, 2000 are not  necessarily  indicative of the results that may
be expected for the year ending May 31, 2000. For further information,  refer to
the  consolidated  financial  statements and footnotes  thereto  included in the
Company's Annual Report on Form 10-K for the year ended May 31, 1999.


2.       INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:

                                   As of                          As of
                              February 29, 2000                May 31, 1999
                              ------------------          --------------------
Raw materials and supplies        $5,042,978                     $3,856,309
Work in process                    1,118,930                        967,889
Finished goods                    10,814,295                     11,240,992
                              ------------------          --------------------
                                 $16,976,203                    $16,065,190
                              ==================          ====================


3.     EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.
<TABLE>
<CAPTION>

                                                         Three Months Ended                 Nine Months Ended
                                                    February 29,     February 28,     February 29,     February 28,
                                                        2000             1999             2000             1999
                                                   ---------------- ---------------  ---------------- ---------------
<S>                                                        <C>            <C>              <C>              <C>

Numerator for basic and diluted earnings per share:
  Income available to common shareholders                $ 837,896       $ 976,097        $3,497,087      $2,320,176
                                                   ================ ===============  ================ ===============


Denominator:
  For basic earnings per share - weighted
  average basis                                          7,816,012       7,459,589         7,715,560       7,711,459

  Effect of dilutive stock options and warrants            855,179         261,091           969,597         269,893
                                                   ---------------- ---------------  ---------------- ---------------
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                       8,671,191       7,720,680         8,685,157       7,981,352
                                                   ================ ===============  ================ ===============

Basic earnings per share                                     $0.11           $0.13             $0.45           $0.30
                                                   ================ ===============  ================ ===============


Diluted earnings per share                                   $0.10           $0.13             $0.40           $0.29
                                                   ================ ===============  ================ ===============

</TABLE>


<PAGE>



4.    DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):
<TABLE>
<CAPTION>

                                                         Three Months Ended February 29, 2000
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>             <C>           <C>          <C>          <C>             <C>              <C>

Net sales:
   Unaffiliated            $12,140        $2,282        $1,601        $1,312        $1,866      $      -         $19,201
customers
   Affiliates                1,682           228             -            78           707        (2,695)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 13,822         2,510         1,601         1,390         2,573        (2,695)         19,201

Income from operations         973           242            83           442           265            10           2,015


                                                         Three Months Ended February 28, 1999
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated            $10,633        $2,619        $1,684          $937          $885      $      -         $16,758
customers
   Affiliates                1,366            88            16            30             -        (1,500)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 11,999         2,707         1,700           967           885        (1,500)         16,758

Income from operations       1,136           470           172           198           (27)           (3)          1,946


                          ----------------------------------------------------------------------------------------------------
                                                          Nine Months Ended February 29, 2000
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated            $37,125        $7,156        $5,020        $3,809        $5,271      $      -         $58,381
customers
   Affiliates                4,935           476             -           230         2,034        (7,675)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 42,060         7,632         5,020         4,039         7,305        (7,675)         58,381

Income from operations       4,629           840           413         1,162           137             2           7,183

                          ----------------------------------------------------------------------------------------------------
                                                          Nine Months Ended February 28, 1999
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated            $23,131        $7,697        $5,083        $3,153        $1,718      $     -          $40,782
customers
   Affiliates                3,413           255            16           123             -        (3,807)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 26,544         7,952         5,099         3,276         1,718        (3,807)         40,782

Income from operations       1,675         1,271           558           821            68           (32)          4,361

</TABLE>

The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,747,000 and $1,726,000 for the three months ended February 29,
2000, and February 28, 1999,  respectively and $5,228,000 and $3,769,000 for the
nine months ended  February 29, 2000 and  February 28, 1999,  respectively.  The
Company's  German  operation made net export sales to unaffiliated  customers of
approximately $624,000 and $618,000 for the three months ended February 29, 2000
and February  28,1999,  respectively  and  $1,118,000  and $992,000 for the nine
months  ended  February  29,  2000 and  February  28,  1999,  respectively.  The
Company's Canadian operation made net export sales to unaffiliated  customers of
approximately $543,000 and $492,000 for the three months ended February 29, 2000
and February 28, 1999,  respectively  and $1,634,000 and $1,899,000 for the nine
months ended  February 29, 2000 and  February  28, 1999,  respectively.  Product
sales to affiliates are valued at market prices.


<PAGE>



5.       COMPREHENSIVE INCOME

The  components  of  comprehensive  income for the  three-month  and  nine-month
periods ended February 29, 2000 and February 28, 1999 are as follows:

<TABLE>
<CAPTION>

                                              Three Months Ended                         Nine Months Ended
                                      February 29,         February 28,         February 29,           February 28,
                                          2000                 1999                 2000                   1999
                                     ----------------     ----------------    ------------------     -----------------

<S>                                        <C>                   <C>                   <C>                   <C>

Net income                                $837,896             $976,097           $3,497,087            $2,320,176
Net foreign currency translation          (308,383)            (877,995)            (653,871)             (153,950)
                                     ----------------     ----------------                           -----------------
                                                                              ------------------
Comprehensive income                      $529,513            $  98,102           $2,843,216            $2,166,226
                                     ================     ================    ==================     =================
</TABLE>


Accumulated  comprehensive  loss as of  February  29,  2000 and May 31, 1999 was
($3,794,651) and ($3,140,780),  respectively. The balance consists of net losses
on  foreign  currency  translation  adjustments  and has been  disclosed  in the
shareholders' equity section of the condensed consolidated balance sheet.


6.   CONTINGENCIES

When the Company  acquired Gamma  Biologicals,  Inc.  ("Gamma  Biologicals")  in
October 1998, Gamma Biologicals was a party to an existing legal proceeding.  On
May 12, 1998, Gamma  Biologicals  received  notification  that a claim of patent
infringement  had  been  filed on that  date in U.S.  District  Court,  Southern
District of Florida,  Miami Division, by Micro Typing Systems, Inc. and Stiftung
fur Diagnostiche Forschung (the Foundation).  Subsequently, in February 1999 the
Company received notification that a second claim was filed in the U.S. District
Court for the  Northern  District of Georgia,  against  Immucor,  Inc. and Gamma
Biologicals for patent  infringement  on the first patent  described above and a
second patent  recently  granted to the  Foundation.  The claim alleges that the
recently  introduced Gamma ReACT Test System infringes U.S. patent No. 5,512,432
granted to the Foundation April 30, 1996 and U.S. patent No.  5,863,802  granted
to the  Foundation on January 26, 1999. The  plaintiffs  seek a preliminary  and
permanent  injunction  against  the  continued  alleged  infringement  by  Gamma
Biologicals and Immucor, and an award of treble damages, with interest and costs
and reasonable  attorney's  fees.  Management is confident that ReACT technology
does not infringe the Foundation's  patents;  however, an unfavorable outcome in
this  action  could have a material  adverse  effect upon the  business  and the
results of operations in a given reporting  period.  Since this matter is in the
earliest stage of proceedings and due to  uncertainties  involved in litigation,
management  cannot  predict the likelihood of a particular  outcome.  Management
believes it has a meritorious defense against the alleged infringement.
<PAGE>


                                 IMMUCOR, INC.

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
 of Operations.

       Any  statements  contained  herein  that  are  not  historical  fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 1999.

Financial Condition and Liquidity:

       During the nine months ended February 29, 2000, the Company increased its
profitability,  generated  positive cash flow from  operations,  and  maintained
positive working  capital.  As of February 29, 2000, the Company's cash position
totaled  $2,976,000.  For the nine months ended  February 29, 2000,  the Company
generated  cash from operating  activities of $1,238,000 and purchased  property
and equipment of $2,797,000.  In December  1999,  the Company repaid  promissory
notes owed to the former  owners of Dominion  Biologicals  Limited of $3,886,000
($5,471,000  in Canadian  dollars)  and  acquired  debt of the same amount to be
repaid over the next three years.  The exercise of  approximately  374,000 stock
options and warrants provided $2,893,000 in cash.

        Management believes that the Company's current cash and cash equivalents
balance,  internally  generated funds, and amounts  available under the lines of
credit should be more than  sufficient to support  operations to support planned
product  introduction  and continued  improvement  and  development  of products
during the next 12 months.  Management  also  believes  additional  credit lines
would be available should the need arise for capital improvements,  acquisitions
or other corporate purposes.

Results of Operations:

Net sales

       Net  sales  for  the  three  months  ended   February  29,  2000  totaled
$19,201,000  an  increase  of  $2,443,000  (15%) over last  year's  $16,758,000.
Current year  three-month  results included an increase in net sales of $558,000
related to Gamma Biologicals, Inc. ("Gamma Biologicals") acquired on October 27,
1998 and $857,000  from Medichim and  Immunochim  acquired on March 15, 1999 and
from BCA, a division  of  Biopool,  acquired on April 30,  1999.  The  remaining
increase  in sales was  primarily  due to  instrumentation  sales.  The  Company
generated  instrument  revenues  of  $2,800,000  for  the  quarter  compared  to
$2,200,000  for the same  period  last  year.  Sales by the  Company's  European
subsidiaries  combined increased 11% over last year's total excluding the effect
of the  acquisitions.  However,  when  translated  into US dollars,  there was a
decrease of 3% due to unfavorable  exchange rates in Europe. For the nine months
ended February 29, 2000, net sales were $58,381,000  (including $19,353,000 from
acquisitions)   compared  to  $40,782,000   (which   includes   $6,354,000  from
acquisitions)  in the  prior  year.  Year to  date  instrument  sales  increased
approximately $4,000,000 over prior year.

Gross profit

       As a percent of sales,  gross profit for the three months ended  February
29, 2000 totaled 53.0% versus 54.7% for the same period in 1999. The decrease in
gross profit margin was  primarily  caused by higher  instrument  sales at lower
gross  margins  than other  products  and the sales  increase  due to prior year
acquisitions  which are at lower gross  profit  margins than  Immucor's  product
lines.  Gross profit for the nine months ended  February 29, 2000 totaled  53.3%
versus 54.5% for the same period in 1999,  and decreased for  substantially  the
same reasons.



<PAGE>



Operating expenses

       When compared to the prior year, research and development costs increased
$140,000 and $283,000 for the three and nine month  periods,  respectively.  The
increase is primarily  due to higher  costs  related to  instrument  development
projects.

       For the quarter ended February 29, 2000,  selling and marketing  expenses
decreased  $47,000,  or 1.5%,  when compared to the same quarter last year. With
the acquisition of Gamma Biologicals, the sales force was realigned resulting in
a reduction of certain  positions due to  duplication  of efforts  offset by the
addition of  personnel  required  for the  Company's  instrumentation  strategy.
Selling and marketing  expense  increased  $1,582,000 year to date with $498,000
attributable  to Medichim and  Immunochim;  and,  higher payroll expense for the
increase in personnel  as the Company has  continued to focus its efforts on the
instrument side of the business.

       Distribution  expenses  increased $458,000 for the three month period and
$2,159,000  for the nine month  period when  compared to the same periods in the
prior year. The increase  relates to a temporary shift in shipping  methods from
ground to  overnight,  change in shipping  specifications  for certain  products
resulting  in higher  costs per  shipment,  increase  in  personnel  and overall
increase in shipping activity.

        General and administrative expenses for the three and nine month periods
increased  $384,000  and  $1,854,000,   respectively,  for  additional  expenses
resulting from the growth of the Company with acquisitions. The Company has also
experienced  an  increase  in  operating  costs  such  as  rent,  utilities  and
depreciation expense with the Company's expansion at its U.S. operations.

       Merger-related  expenses for the prior year are one-time expenses related
to the Gamma Biologicals and BCA acquisitions.

       Amortization expense for the three and nine months periods ended February
29,  2000,  increased  $124,000  and  $643,000  due to goodwill  recorded in the
acquisitions of Gamma  Biologicals on October 27, 1998,  Medichim and Immunochim
on March 15, 1999 and BCA, a division of Biopool, on April 30, 1999.

Interest income

       Interest  income  decreased  $16,000 for the quarter and $291,000 for the
nine month period due to lower cash  balances as compared to last year caused by
the purchase of treasury stock and the purchase of Gamma  Biologicals  and other
acquisitions which were partially funded by the use of the Company's cash.

Interest expense

       When  compared to the prior year three and nine month  periods,  interest
expense increased  $190,000 and $1,243,000.  This is a result of the purchase of
Gamma Biologicals and other  acquisitions which were primarily financed with the
proceeds of a bank loan.

Other income

       Other income increased $3,000 for the three month period and $102,000 for
the nine month  period as compared to the same  periods  last year.  The year to
date increase is primarily due to foreign  currency  transaction  gains realized
earlier in the fiscal year versus losses in the same period last year.


<PAGE>



Income taxes

       Income  tax  expense  as a percent  of pretax  income  is  evaluated  and
adjusted on an ongoing  basis as the  Company  continues  implementation  of tax
planning strategies.  For the nine months ended February 29, 2000, the Company's
effective tax rate was 33.2% compared to 39.6% for the same period last year.


Year 2000

       The  Company  and its  subsidiaries  have not  experienced  any  material
problems with network  infrastructure,  software,  hardware and computer systems
relating to the inability to recognize appropriate dates and computer related to
the year 2000.  The Company and its  subsidiaries  do not  anticipate  incurring
material  expenses or  experiencing  any material  operational  disruptions as a
result of any Year 2000 issues.


ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk

       There have been no material  changes  regarding the Company's market risk
position from the information provided in its Annual Report on Form 10-K for the
fiscal year ended May 31, 1999. The  quantitative  and  qualitative  disclosures
about  market  risk are  discussed  in Item  7A-  Quantitative  and  Qualitative
Disclosures About Market Risk, contained in the Company's Form 10-K.



PART 11 - OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

         27 Financial data schedule.

         (b) The  Company  did not file any reports on Form 8-K during the three
         months ended February 29, 2000.

<PAGE>


SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                                   IMMUCOR, INC.
                                  (Registrant)



Date: April 14, 2000








/s/  Edward L. Gallup          Edward L. Gallup, President
-------------------------







/s/  Steven C. Ramsey          Steven C. Ramsey, Senior Vice President - Finance
-------------------------          (Principal Accounting Officer)